Early Assessment of Anthracycline-induced Cardiotoxicity (CARDIOTOX)
Study Details
Study Description
Brief Summary
Anthracycline-based chemotherapy is a key point of the treatment of patients with Hodgkin's and non-Hodgkin's lymphomas. However, cumulative doses are limited by cardiotoxicity, resulting in a marked left ventricular function impairment that may lead to heart failure.
The standard clinical approach to monitoring for anthracycline cardiotoxicity is based on cardiac function monitoring using echocardiography or radionuclide angiography. The aim of this study is to evaluate the usefulness of biochemical markers of cardiac injury (troponin and NT-proBNP) and structural changes on cardiac MR in predicting anthracycline cardiotoxicity.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically proven lymphoma (Hodgkin's or non-Hodgkin's)
-
Age > 18 y/o and < 70 y/o
-
WHO score < or = 2
-
Life expectancy > 6 mo
-
Left ventricular ejection fraction > 50%
-
Informed consent
Exclusion Criteria:
-
Previous chemotherapy using anthracyclines
-
History of radiation therapy
-
History of congestive heart failure
-
History of chronic renal insufficiency
-
Contra indication to MR examination
-
Atrial fibrillation and significant arrhythmia
-
Pregnancy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University Hospital of Rouen | Rouen | France | 76031 | |
| 2 | Centre Henri Becquerel | Rouen | France | 76038 |
Sponsors and Collaborators
- Centre Henri Becquerel
- Ligue contre le cancer, France
Investigators
- Study Chair: Alain Manrique, MD, Centre Henri Becquerel
- Principal Investigator: Fabrice Jardin, MD, Centre Henri Becquerel
Study Documents (Full-Text)
None provided.More Information
Publications
- Cardinale D, Sandri MT, Martinoni A, Borghini E, Civelli M, Lamantia G, Cinieri S, Martinelli G, Fiorentini C, Cipolla CM. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol. 2002 May;13(5):710-5.
- Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol. 2003 Mar-Apr;10(2):132-9.
- Okumura H, Iuchi K, Yoshida T, Nakamura S, Takeshima M, Takamatsu H, Ikeno A, Usuda K, Ishikawa T, Ohtake S, Matsuda T. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol. 2000;104(4):158-63.
- Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998 Sep 24;339(13):900-5. Review.
- 2005-001-CHB